What is the recommended dosing frequency of fosfomycin (oral and intravenous) for adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Fosfomycin Dosing Frequency

For uncomplicated urinary tract infections in adults, oral fosfomycin is given as a single 3-gram dose, while intravenous fosfomycin for complicated infections requires 6 grams every 8 hours.

Oral Fosfomycin (Adults)

The standard regimen for uncomplicated cystitis is a single oral dose of 3 grams 1, 2, 3, 4, 5, 6. This single-dose approach is supported by multiple international guidelines including IDSA/ESCMID, European Association of Urology, and American College of Physicians recommendations.

Off-Label Multi-Dose Regimens

For complicated lower urinary tract infections where single-dose therapy may be inadequate, 3 grams orally every 48-72 hours for a total of 3 doses has been used off-label 7. This regimen is particularly relevant for:

  • Patients who failed first-line therapy
  • Multidrug-resistant pathogens (including VRE, ESBL-producing organisms)
  • Patients intolerant to standard agents

Important caveat: The bacterial eradication rate with oral fosfomycin is lower than other first-line agents for cystitis, though clinical cure rates remain comparable 2. Oral fosfomycin is not recommended for pyelonephritis due to insufficient evidence for upper tract infections 5.

Intravenous Fosfomycin (Adults)

For complicated upper urinary tract infections or acute pyelonephritis, the dosing is 6 grams IV every 8 hours 7, 8, 9. Treatment duration:

  • 7 days for uncomplicated cases
  • 14 days if concurrent bacteremia is present

The ZEUS trial demonstrated this regimen was noninferior to piperacillin-tazobactam and showed superior microbiological eradication against ESBL-producing Enterobacterales and carbapenem-resistant organisms 7, 8. This makes IV fosfomycin particularly valuable as a carbapenem-sparing option in complicated UTIs with resistant pathogens.

Critical Illness Considerations

In critically ill patients, particularly those on kidney replacement therapy, 8 grams three times daily (24 g/day total) may be required to achieve bactericidal concentrations against organisms with MIC ≥64 mg/L 9.

Pediatric Dosing

The provided evidence does not contain specific pediatric dosing recommendations for fosfomycin. Historical data suggests 50-100 mg/kg/day divided doses for 5 days was used in children for various infections 10, 11, but contemporary pediatric guidelines are not included in the available evidence.

Pharmacokinetic Rationale

The single-dose oral regimen is justified because fosfomycin achieves urinary concentrations >128 mg/L that persist for 24-48 hours after a 3-gram dose 6, 12. Peak urinary concentrations reach 706-1053 mg/L within 2-4 hours under fasting conditions. Approximately 38% is excreted unchanged in urine with a half-life of 5.7 hours 6, 13.

Food reduces bioavailability from 37% to 30%, but the drug can be taken without regard to meals since total urinary excretion remains unchanged 6.

Key Clinical Pitfalls

  • Do not use oral fosfomycin for pyelonephritis or bacteremia - insufficient systemic concentrations
  • Avoid metoclopramide co-administration - significantly reduces fosfomycin serum and urinary concentrations 6, 13
  • Renal adjustment: In severe renal impairment (CrCl <10 mL/min), half-life extends to 50 hours; hemodialysis extends it to 40 hours 6, 13
  • The FOREST trial showed IV fosfomycin failed noninferiority in MDR bacteremia with higher treatment-limiting adverse effects 8 - use caution in hemodynamically unstable patients with bacteremia

References

Research

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2020

Research

Intravenous Fosfomycin in Complicated Urinary Tract Infection.

The Annals of pharmacotherapy, 2026

Research

[Clinical trial of fosfomycin for Campylobacter enteritis].

The Japanese journal of antibiotics, 1984

Research

Fosfomycin Tromethamine: A Urinary Antibiotic.

The Journal of the Association of Physicians of India, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.